Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

MVision AI Is Selected To Provide Its Contour+ Solution By The Republic Of Ireland’s Health Service Executive (HSE) For Its First Installation In The Country

MVision AI

MVision AI is experiencing ongoing and rapid growth within the health service sector globally. The company is delighted to announce that we have successfully been awarded the tender from the Republic of Ireland’s Health Service Executive (HSE) for the installation of our Contour+ auto contouring solution at Cork University Hospital. "MVision AI are truly delighted to have been selected as the preferred supplier of an AI auto contouring system to Cork University Hospital. This will be the first deployment of our Guideline Based Contour+ solution via our Cloud service within this country," says Stewart Pegrum, MVision AI's Vice President of Global Sales. The procurement was undertaken via a national EU tender process, which was published on 3rd February 2023 Each tender applicant was evaluated on Qualitative Selection Criteria including; Economic and Financial Standing, Technical and Professional Ability and Quality Assurance Standards. Tenders that achieve the minimum requirements set out in the Qualitative Selection Criteria were then evaluated to determine which presented the most economically advantageous tender using the award criteria below: Project Management & Installation (5%) Primary Requirements (5%) Functional Requirements (10%) Clinical Requirements (25%) ICT Technical Requirements (10%) Service & Support (5%) Training & Documentation (5%) Sustainability (5%) Cost (30%) As part of the clinical requirements sample delineations for a selection of structures were requested for evaluation purposes from the Tenderers. These were reviewed by the tender panel that was made up of Medical Physicists, Radiation Oncologists, Radiation therapists and HSE procurement representatives. " We recently started SABR Lung treatments and expect to introduce SABR Liver and SRS treatments in the near future. We hope MVision will help us to standardize contouring in line with best practice guidelines and reduce the time spent delineating patient datasets by approximately 50%, " says Mr. Michael Roche, Principal Physicist, Medical Physics Department in Cork University Hospital. MVision AI's interests in the UK and Ireland are represented by our longstanding distributor, Xiel, which specializes in providing solutions for Nuclear Medicine, Radiotherapy, and Diagnostic Radiology. "We are delighted that CUH have selected MVision AI as their solution for auto contouring, this was a very stringent process with much interaction and this award demonstrates the robust capabilities of Contour +", says Phil Neale, Xiel's Key Account Consultant in Radiotherapy Physics. About MVision AI MVision AI is an innovative software service provider for radiotherapy treatment planning. Our AI-powered automatic segmentation tool, Contour+, helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. MVision AI is the AI-powered radiotherapy planning solution for treating cancer; MVision AI uses artificial intelligence to automate cancer treatment planning with its unique guideline-based AI contouring - Contour+; MVision AI announced the new guideline-based automatic segmentation service Contour+ release version 1.2.4 [1]; MVision AI's Contour+ has been officially recommended by NICE (National Institute for Health and Care Excellence) for use within the NHS, alongside several other AI auto-contouring tools[2]; MVision AI process a staggering 2750 scans per month, translating to nearly a quarter of all radiotherapy patients in the UK benefiting from Contour+; The next-generation technology speeds up the entire cancer treatment process, significantly reducing treatment planning time from weeks to days; According to information from the Irish Cancer Society, cancer is the leading cause of death in Ireland: an estimated 44,000 people in Ireland are diagnosed with cancer each year [3]; The scalable platform enables the improvement of cancer treatments worldwide. Contour+ has already been used in treating over 170,000 cancer patients in 16 countries. MVision.ai - Press Release: MVision AI launches Contour+ auto-contouring to facilitate standardization and shorten time to treatment for cancer radiotherapy MVision.ai - Exciting News: AI Auto-Contouring Recommended by NICE for Radiotherapy in the NHS! Irish Cancer Society - Cancer statistics MVision.ai MVision AI Linkedin page MVision AI Media Kit Interview requests: Alena Kruhlova alena.kruhlova@mvision.ai About Cork University Hospital (CUH) Currently Cork University Hospital (CUH) treats c.2000 patients annually. At present, the majority of volume delineation is a time-consuming process and is manually performed by CUH's 7 Consultant Radiation Oncologists who may be assisted at times by other staff members including Dosimetrists or Radiation Therapists. A new radiotherapy facility was opened in 2019. CUH.hse.ie Cork University Hospitals Linkedin Group About Xiel. Xiel is a specialist distributor of medical technologies in the UK and Ireland. We work with global leading solution providers; therefore, continuously improving efficiency and quality for our customers. Our partners research and develop highly specific products for what is often a small world market. The expertise of Xiel lies in our deep understanding of the structure and organisation of radiotherapy departments in the UK and Ireland, for us to advise on the best solutions possible. Xiel. Exceptional Products. Extraordinary Service. Everyday. Xiel.co.uk Xiel Linkedin page Contact Details MVision AI Alena Kruhlova alena.kruhlova@mvision.ai Company Website https://www.mvision.ai/

September 14, 2023 07:17 AM Eastern Daylight Time

Image

News Release

Principal Technologies laser focussed on acquiring healthcare tech to launch in North America

Principal Technologies

Jerry Trent, CEO of Principal Technologies joined Steve Darling from Proactive to share insights in a recent interview about the company's focus on healthcare technology companies in Europe. The company aims to identify local champions with exceptional healthcare technologies that are often limited to specific regions. Principal Technologies plans to leverage its access to these opportunities, helping them expand globally and bridge valuation gaps between European assets and the North American market. The company's strategic focus includes businesses with proven technologies and databases of patient information. The goal is to create a conglomerate of participations with synergies to benefit patients and shareholders. Principal Technologies has also acquired a clinical research organization (to facilitate efficient international distribution rights for healthcare tech companies while expanding its database. Trent mentioned that they are actively exploring significant acquisitions in line with their criteria, signaling exciting growth prospects for Principal Technologies in the coming months. The interview revealed the company's commitment to improving healthcare globally, driven by a seasoned team and guided by Liechtenstein's Prince, offering a promising future for the company and its stakeholders. Stay tuned for more updates on Principal Technologies' developments. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 13, 2023 02:00 PM Eastern Daylight Time

Video

News Release

Rakovina Therapeutics continues to make progress as company provides corporate update

Rakovina Therapeutics Inc

Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report. Bacha highlighted several significant developments for the company during this period: including a publication in the Journal of Clinical Oncology. Rakovina Therapeutics published a paper in the Journal of Clinical Oncology describing pre-clinical data for its lead pre-clinical candidate, kt-3283. This data demonstrates the potential of kt-3283 to treat cancers that are resistant to first-generation PARP inhibitors. This development is crucial as it suggests that Rakovina's compound could address unmet medical needs in the treatment of various treatment-resistant cancers, including Ewing sarcoma. Bacha also said the company presented at the American Association of Cancer Research. The company presented new preclinical in vitro and in vivo data at the annual meeting of the American Association of Cancer Research. This data demonstrated the potential of Rakovina's kt-3000 series in treating treatment-resistant Ewing sarcoma, a rare childhood tumor. The kt-3000 series is a novel class of DNA-damage response inhibitors designed to selectively inhibit two important anti-cancer targets: poly(ADP) ribose polymerase (PARP) and histone deacetylase (HDAC). These developments reflect Rakovina Therapeutics' commitment to advancing innovative treatments for challenging and resistant cancers. The company's research and progress in the field of cancer therapy offer hope for patients and represent significant strides in addressing unmet medical needs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 13, 2023 01:30 PM Eastern Daylight Time

Video

xCures Platform advances progress on the White House Cancer Moonshot mission to end cancer as we know it.

xCures

xCures, a leader in data-driven cancer solutions, is thrilled to announce that its platform has been highlighted as a new commitment to deliver progress on the White House Cancer Moonshot mission – ending cancer as we know it. The xCures health-data technology platform has been designed to overcome a key challenge for many rare diseases: collecting, organizing, and standardizing comprehensive data from patients across the US. In alignment with the Cancer Moonshot Initiative’s goals to reduce cancer death rates by 50% over the next 25 years, xCures is launching an ambispective natural history study of DMG and DIPG. This study will speed up the identification of patterns that can inform more personalized treatment plans and targeted therapies. xCures will provide access without licensing fees to the data for academic and government researchers. Open access to this valuable resource will accelerate scientific breakthroughs and foster a community actively seeking a cure. “We recognize that collaboration is key to success. Our pledge extends to fostering an ongoing relationship with all stakeholders - patients, families, physicians, researchers, and advocacy organizations,” said Mika Newton, CEO of xCures. “Together, we can create a powerful collective dedicated to advancing the understanding and treatment of DMG DIPG.” DMG and DIPG patients are encouraged to sign up for the study at www.xcures.com/dmg About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. Contact Details xCures Inc Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

September 13, 2023 01:04 PM Eastern Daylight Time

Microban launches Ascera™: a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International

Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world. As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product. “Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.” “As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle." Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today! *The Microban ® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications. Contact Details Audrey Jestin at kdm communications limited, St Neots, UK +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

September 13, 2023 10:00 AM Eastern Daylight Time

Image

Microban launches Ascera™: a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International

Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world. As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product. “Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.” “As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle." Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today! *The Microban® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications Contact Details Audrey Jestin at kdm communications limited, St Neots, UK +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

September 13, 2023 10:00 AM Eastern Daylight Time

What’s Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field

COMPASS Pathways

By Rachael Green, Benzinga In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of $125 million and the potential for an additional investment of up to $160 million if the warrants are fully exercised for cash. This will aim to support the phase 3 trials in treatment-resistant depression (TRD) and phase 2 programs in anorexia nervosa and PTSD. The news seems like a major tailwind for COMPASS, which sits at the forefront of an emerging psychedelics market growing at an estimated 13.49% compound annual rate and anticipated to balloon from a market cap of $4.87 billion in 2022 to $11.82 billion in 2029. This also marks a major shift in how psychedelic drug development is funded, with more traditional investors eying this novel area of science that has the potential to address large, unmet needs in mental health care – and doing so through the traditional regulatory pathway that would require FDA approval. This financing comes on the heels of additional validation for COMPASS when, in May, the U.S. Patent Trial and Appeal Board (the PTAB) upheld two key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used by COMPASS in their phase 3 clinical trials for treatment-resistant depression (TRD). Last summer the PTAB denied the institution of post-grant reviews, finding that the challenger failed to establish that the claims in the patents were unpatentable, and in May the PTAB rejected requests for rehearing of these decisions. The Need For Better Options To Combat Mental Health Crisis Spurs Psychedelics Market Momentum Once a relatively fringe area of research, studies involving psychedelics are gradually becoming more common as data continues to reinforce the therapeutic potential of psilocybin, LSD, MDMA and other psychoactive compounds. At the same time, the global mental health crisis has gained increasing attention as the pandemic exacerbated the existing problem and made the need for more diverse treatment options apparent. According to the World Health Organization (WHO), an estimated 26% and 28% of the global population live with anxiety and depression, respectively. Meanwhile, 40 million people have bipolar disorder, 24 million have schizophrenia, and 14 million have an eating disorder. During the pandemic, the crisis reached a tipping point as the number of people contemplating suicide doubled, and the number of suicide attempts increased. The antidepressants, mood stabilizers and antipsychotics currently available do provide relief for some, but many people must first go through a period of trial and error with different medications before they find the right one and the right dosage. But for some patients – including one-third of patients living with treatment-resistant depression – the right medication doesn’t yet exist. Growing awareness of that reality has made both regulators and researchers more open to exploring the potential of psychedelics. In fact, in June the FDA issued guidance on developing psychedelic medicines. Early results so far are encouraging and have brought new hope to the millions of people around the world struggling with mental illness. Psilocybin has been shown in clinical trials to improve mood, reduce anxiety and lower depression symptoms. In COMPASS's phase 2b trial in treatment-resistant depression (TRD), 30% of patients achieved remission by the third week after taking just one 25-milligram dose of COMP360 psilocybin with psychological support at the start of the trial. At the 12-week follow-up, over 20% of patients were still in remission. Compass Pathways Carves Out A Path For Novel Psilocybin Treatment Compass’s research is focused on psilocybin. Its patented, investigational COMP360 is a synthetic formulation of the psychoactive compound found in psilocybin mushrooms, commonly known as magic mushrooms. But for COMPASS, it’s not just about developing a novel psychedelic treatment but ensuring that the market infrastructure and regulatory framework exist for any new FDA-approved treatment to reach the patients who need it. To that end, COMPASS has been working on advancing research and laying the groundwork to ensure its COMP360 psilocybin treatment, if approved by regulatory authorities, can be integrated fully and effectively into existing health systems. One of the most recent milestones achieved through that collaborative approach is the addition of new Current Procedural Terminology III (CPT) codes for psychological support during the administration of psychedelic therapies. Taking effect in January 2024, the new CPT codes give healthcare providers a way to document these treatments in medical records and seek reimbursement from payers for psychological support during the administration of any FDA-approved treatment. Topline data from Compass’s first phase 3 trial for treatment-resistant depression is expected in the summer of 2024. A second phase 3 trial for TRD evaluating an alternate dosing regimen for the psilocybin treatment where a second dose is administered in the third week is expected to read out topline data in mid-2025. While its TRD program is the furthest along in the clinical trial process, Compass also has clinical and preclinical programs to evaluate COMP360 as a treatment for anorexia and PTSD, as well as other novel compounds that could treat a variety of mental health conditions. There are also a number of investigator-initiated trials using investigational COMP360 for conditions ranging from major depressive disorder to obsessive-compulsive disorder as well. Company BioCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Stephen Schultz stephen.schultz@compasspathways.com

September 13, 2023 09:00 AM Eastern Daylight Time

Poolbeg Pharma "moving forward rapidly" with POLB001

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023. Skillington highlights Poolbeg's "healthy" financial position and attributes it to low operational cash burn and strong financial discipline. Skillington also emphasises cost-effective R&D, citing examples like the LPS challenge study and AI programs that utilise supercomputers for efficiency. They continue to seek non-diluted funding opportunities to support infectious disease programs, following a €2.3 million grant from the Irish government in 2022 for an oral vaccine program. Operational achievements include positive results from a POLB001 LPS human challenge trial, showing potential in treating acute inflammatory conditions and oncology-related issues. The company's collaboration with CytoReason identified valuable drug targets for influenza treatment. Additionally, progress was noted in oral vaccine delivery and clinical trials for an oral GLP-1 agonist. Skillington hinted at new indications for POLB001 in the oncology sector, addressing cytokine release syndrome, a significant market opportunity. Future milestones include RSV dataset validation, oral vaccine encapsulation, and influenza drug target validation. The company remains focused on clinical trial preparations and partnerships with pharmaceutical companies, reflecting a proactive approach to advancing their programs. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 13, 2023 08:58 AM Eastern Daylight Time

Video

News Release

BioVie chief social impact officer sees major need for Alzheimer’s support and research

BioVie Inc

BioVie chief social impact officer Sarah Hoit joined Steve Darling from Proactive to talk about the growing need for support for individuals suffering from Alzheimer's Disease and their caregivers, including family members. Hoit emphasized that while research into Alzheimer's treatments and cures is ongoing, it remains a significant challenge. The quest for effective treatments and potential cures is a critical aspect of addressing the Alzheimer's crisis. Hoit addressed how BioVie is helping on the clinical side with a very unique and different approach. Additionally, she shed light on the rising costs associated with Alzheimer's care, which have significant financial implications for both healthcare systems and families. The financial burden of Alzheimer's care often falls on families, and the cost of care can be substantial. Moreover, the interview highlights the importance of brain health throughout one's life, not just in seniors, and the role of epigenetics in controlling around 70% of health outcomes. Hoit also introduced Social Impact Partners, a global brain health initiative, and encourages collaboration between the private sector, nonprofits, and governments to combat the dementia crisis. Overall, the discussion underscored the urgent need for ongoing research, treatment development, and support systems for individuals and families affected by Alzheimer's disease. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

September 12, 2023 02:10 PM Eastern Daylight Time

Video

1 ... 93 94 95 96 97 ... 303